ANAVEX LIFE SCIENCES CORP. (AVXL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | (m) | Liabilities, Current |
| Cash and equivalents | 118.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $118.33M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $127.42M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $131.75M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $102.58M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $101.16M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $115.77M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $120.78M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $132.19M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $138.76M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $139.39M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $143.76M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $151.02M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $154.82M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $153.47M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $143.62M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $149.16M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $9.48M | $153.20M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $8.07M | $153.34M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $10.53M | $151.15M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $152.11M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $157.56M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $7.76M | $75.86M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $8.03M | $47.36M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $29.25M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $6.95M | $27.62M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $6.23M | $26.56M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.46M | $27.46M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $5.04M | $22.19M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $4.34M | $21.25M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $6.37M | $19.46M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.88M | $20.72M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $3.88M | $22.93M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $3.21M | $25.83M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $3.42M | $25.66M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.80M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $3.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $1.45M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $2.12M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.19M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $3.19M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $2.17M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.43M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.53M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $2.66M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.35M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.53M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.42M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $1.44M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.90M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $1.88M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $1.82M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.95M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $2.89M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |